Structure Therapeutics Inc.
GPCR
$56.65
$2.905.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.45% | 11.78% | 39.72% | 18.60% | 23.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -129.20% | 60.98% | 111.46% | 75.89% | 51.84% |
| Operating Income | 129.20% | -60.98% | -111.46% | -75.89% | -51.84% |
| Income Before Tax | 191.28% | -93.61% | -136.80% | -79.70% | -46.46% |
| Income Tax Expenses | 25.00% | 17.39% | 162.26% | 237.93% | 143.59% |
| Earnings from Continuing Operations | 190.47% | -93.40% | -136.85% | -79.88% | -48.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 190.47% | -93.40% | -136.85% | -79.88% | -48.88% |
| EBIT | 129.20% | -60.98% | -111.46% | -75.89% | -51.84% |
| EBITDA | 130.93% | -61.12% | -112.07% | -76.26% | -51.42% |
| EPS Basic | 181.78% | -89.17% | -103.36% | -46.06% | -20.34% |
| Normalized Basic EPS | 235.21% | -89.36% | -103.32% | -45.93% | 8.72% |
| EPS Diluted | 181.78% | -89.17% | -103.36% | -46.06% | -20.34% |
| Normalized Diluted EPS | 235.21% | -89.36% | -103.32% | -45.93% | 8.72% |
| Average Basic Shares Outstanding | 10.63% | 2.24% | 16.47% | 23.15% | 23.72% |
| Average Diluted Shares Outstanding | 10.63% | 2.24% | 16.47% | 23.15% | 23.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |